Sernivo

— THERAPEUTIC CATEGORIES —
  • Psoriasis

Sernivo Generic Name & Formulations

General Description

Betamethasone (as dipropionate) 0.05%; spray.

Pharmacological Class

Corticosteroid.

How Supplied

Spray—60mL, 120mL

Manufacturer

Generic Availability

NO

Sernivo Indications

Indications

Mild to moderate plaque psoriasis.

Sernivo Dosage and Administration

Adult

≥18yrs: apply to affected areas twice daily for up to max 4 weeks; discontinue when control is achieved. Do not occlude.

Children

<18yrs: not recommended.

Sernivo Contraindications

Not Applicable

Sernivo Boxed Warnings

Not Applicable

Sernivo Warnings/Precautions

Warnings/Precautions

Not for oral, ophthalmic, or intravaginal use. Avoid use on face, scalp, axilla, groin, or other intertriginous areas. Do not use on pre-existing skin atrophy. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, reduce dose, or substitute with less potent corticosteroid if occurs. Potential risk of posterior subcapsular cataracts and glaucoma. Avoid abrupt cessation in chronic use. Reevaluate periodically. Pregnancy. Nursing mothers: avoid infant exposure.

Sernivo Pharmacokinetics

See Literature

Sernivo Interactions

Not Applicable

Sernivo Adverse Reactions

Adverse Reactions

Pruritus, burning, stinging, pain, atrophy; allergic contact dermatitis (discontinue if irritation occurs), HPA axis suppression (esp. in children), visual disturbances; rare: Cushing's syndrome, hyperglycemia, glucosuria.

Sernivo Clinical Trials

See Literature

Sernivo Note

Not Applicable

Sernivo Patient Counseling

See Literature

Images